Transgene and NEC: Promising progress with the TG4050 vaccine

Transgene and NEC announce encouraging results for the therapeutic vaccine TG4050, developed for head and neck cancers. Phase I data show that all treated patients are in remission and recurrence-free after two years. TG4050 targets specific neoantigens, inducing a durable CD8+ T cell response.

At the ASCO 2025 conference, results demonstrated promising safety and efficacy. The vaccine, based on NEC's myvac® platform and AI, appears well tolerated with no unexpected adverse effects.

Development of TG4050 continues in Phase II, with the goal of confirming initial results in a larger population. Researchers hope to expand the use of this personalized treatment in adjuvant settings.